ArticleFrontiers in nutrition2026
Novel nutraceutical combination restores hepatic deiodinase expression and protein levels under inflammatory conditions: evidence from an
Article in Frontiers in nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Metabolic dysregulation and biological age acceleration in Hashimoto's thyroiditis: a cross-sectional study based on clinical biomarker aging indices and metabolomics.Frontiers in endocrinology · 2026Article
- Long-term TSH suppression in metabolically unhealthy survivors of differentiated thyroid cancer: a cardiovascular perspective.Frontiers in cardiovascular medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/objectives: Thyroid hormone activation depends on the conversion of T4 to T3 by the selenoenzyme DIO1, whose expression is suppressed by inflammation and oxidative stress. This study evaluated whether a combination of vitamin A, selenium, taurine, oleic acid, and resveratrol could counteract Lipopolysaccaride (LPS)-induced downregulation of DIO1 in HepG2 cells. Methods: Cytotoxicity of Taurine, Resveratrol, Retinol, and Oleic acid was assessed in FB789 and HepG2 cells by MTT assay. Non-toxic, biologically active concentrations (2.5 μM Taurine; 2.5 μM Resveratrol; 50 μM Retinol; 100 μM Oleic Acid) were used to test DIO1 modulation following LPS exposure (1 μg/mL). Results: All compounds exhibited acceptable cell viability profiles at low-to-mid range doses. LPS markedly suppressed Conclusion: In this
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.